45 completed, 6 terminated, 2 unknown, 2 withdrawn. 22 Phase 2, 17 Phase 3, 11 Phase 1, 4 Phase 4, 1 Not applicable.
Follow Chronic Hepatitis C Infection: new trials by email Literature Review of Chronic Hepatitis C Infection trials Research Report on Chronic Hepatitis C Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HEPATITIS C SCREENING in ADULTS with RISK FACTORS in FIVE CITIES of COLOMBIA'S CARIBBEAN COAST (FIVE-CC) Chronic Hepatitis C Infection | Not yet recruiting | Diana Rocio Chavez Bejarano | 4000 | 2025-04-01 | 2025-03-28 | |
| Therapeutic Hepatitis C Virus Vaccine HCVax - Chronic Hepatitis C Infection | Phase 1 | Unknown | GeneCure Biotechnologies | 30 | 2021-04-20 | 2021-09-29 |
| Triple Combination DAAs for Treating HCV GT1b Subjects SOF+DCV+SMV - Chronic Hepatitis C Infection | Phase 2 | Withdrawn | Humanity and Health Research Centre | 2016-12-01 | 2017-05-12 | |
| A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin - Chronic Hepatitis C Infection | Phase 2 / Phase 3 | Completed | AbbVie | 64 | 2015-10-28 | 2021-10-05 |
| A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma ombitasvir/paritaprevir/ritonavir and dasabuvir, ombitasvir/paritaprevir/ritonavir, ribavirin - Chronic Hepatitis C Infection | Phase 3 | Terminated | AbbVie | 3 | 2015-07-01 | 2017-12-12 |
| Switching Regimen in Treating Cirrhotic HCV GT1b Subjects PR4 + LDV/SOF + ASV 4 wk, PR4 + LDV/SOF + SMV 4 wk, PR4 + LDV/SOF + ASV 6 wk - Chronic Hepatitis C Infection | Phase 2 | Completed | Humanity and Health Research Centre | 138 | 2015-05-15 | 2025-03-26 |
| Follow up of IFN Vs DAAs HCV SVR (IFDACS Study) Chronic Hepatitis C Infection | Completed | Humanity and Health Research Centre | 1210 | 2015-05-15 | 2025-03-24 | |
| Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients sofosbuvir and daclatasvir, ledipasvir/sofosbuvir - Chronic Hepatitis C Infection | Phase 3 | Completed | Humanity and Health Research Centre | 48 | 2015-05-01 | 2018-03-19 |
| A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil ombitasvir/paritaprevir/ritonavir and dasabuvir, ribavirin - Chronic Hepatitis C Infection | Phase 3 | Completed | AbbVie | 222 | 2015-04-27 | 2017-08-01 |
| A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection ombitasvir/paritaprevir/ritonavir and dasabuvir, Sofosbuvir, Ribavirin - Chronic Hepatitis C Infection | Phase 2 | Completed | AbbVie | 29 | 2015-02-03 | 2017-12-20 |
| DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO) Ledipasvir/Sofosbuvir, Sofosbuvir and Daclatasvir, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir - Chronic Hepatitis C Infection, HBV Coinfection | Phase 2 / Phase 3 | Completed | Humanity and Health Research Centre | 23 | 2015-02-01 | 2021-09-01 |
| SOF Plus DCV in Treating Chinese Treatment-experienced HCV Patients Sofosbuvir, Daclatasvir - Chronic Hepatitis C Infection | Phase 2 / Phase 3 | Completed | Humanity and Health Research Centre | 106 | 2015-01-01 | 2018-03-19 |
| Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients SOF+RBV, SOF+DCV, LDV/SOF - Chronic Hepatitis C Infection | Phase 4 | Completed | Humanity and Health Research Centre | 112 | 2015-01-01 | 2018-03-19 |
| Neutrino Regimen for Treatment-experienced HCV GT1 Patients SOF+PEG+RBV - Chronic Hepatitis C Infection | Phase 4 | Completed | Humanity and Health Research Centre | 32 | 2015-01-01 | 2016-08-22 |
| Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects LDV/SOF+ASV, SOF+DCV+SMV, SOF+DCV+ASV - Chronic Hepatitis C Infection | Phase 2 | Completed | Humanity and Health Research Centre | 18 | 2015-01-01 | 2016-03-01 |
| Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions Telaprevir, Boceprevir, Sofosbuvir - Chronic Hepatitis C Infection | Completed | Valme University Hospital | 1128 | 2014-12-01 | 2022-06-29 | |
| A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir - Chronic Hepatitis C Infection, Compensated Cirrhosis | Phase 3 | Completed | AbbVie | 60 | 2014-09-01 | 2021-07-12 |
| The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis Chronic Hepatitis C Infection | Completed | University Health Network, Toronto | 106 | 2014-01-01 | 2016-11-29 | |
| Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection ABT-450/r/ABT-267, Placebo - Chronic Hepatitis C Infection | Phase 3 | Completed | AbbVie | 363 | 2013-12-01 | 2018-06-06 |
| Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV Pegylated Interferon Lambda-1a, Daclatasvir (DCV), Ribasphere (RBV) - Chronic Hepatitis C Infection | Phase 3 | Terminated | Bristol-Myers Squibb | 453 | 2013-07-11 | 2023-06-13 |
Showing 20 of 56. Sign in to see all of them.
Hepatitis C (30) · Hepatitis C, Chronic (13) · Fibrosis (2) · Hepatitis, Chronic (2) · Fatty Liver (1) · Hemophilia A (1) · Hepatitis (1) · Insulin Resistance (1) · Metabolic Syndrome (1)
Digestive System Diseases (34) · Liver Diseases (34) · Blood-Borne Infections (32) · Communicable Diseases (32) · Flaviviridae Infections (32) · Hepatitis (32) · Hepatitis, Viral, Human (32) · Infections (32) · RNA Virus Infections (32) · Virus Diseases (32) · Pathologic Processes (16) · Pathological Conditions, Signs and Symptoms (16) · Chronic Disease (15) · Disease Attributes (15) · Hepatitis, Chronic (13)
Ribavirin (30) · paritaprevir (21) · dasabuvir (19) · ombitasvir (19) · Viekira Pak (13) · Sofosbuvir (9) · Ritonavir (8) · daclatasvir (7) · peginterferon alfa-2a (7) · ledipasvir, sofosbuvir drug combination (6) · ledipasvir (5) · Simeprevir (4) · telaprevir (3) · ABT-072 (2) · Valacyclovir (2)
AbbVie (11) · AbbVie (prior sponsor, Abbott) (10) · Humanity and Health Research Centre (9) · Merck Sharp & Dohme LLC (4) · Gilead Sciences (2) · Janssen R&D Ireland (2) · VA Office of Research and Development (2) · Alexion Pharmaceuticals, Inc. (1) · Beth Israel Medical Center (1) · Bristol-Myers Squibb (1) · Diana Rocio Chavez Bejarano (1) · GeneCure Biotechnologies (1) · HanAll BioPharma Co., Ltd. (1) · Kirby Institute (1) · Nottingham University Hospitals NHS Trust (1)
United States (14) · China (8) · Germany (6) · Spain (4) · United Kingdom (4) · Belgium (3) · Canada (3) · France (3) · Italy (2) · Poland (2) · Puerto Rico (2) · Argentina (1) · Australia (1) · Austria (1) · Czechia (1)
George Lau, MD (4) · Dan Cohen, MD (2) · Daniel Cohen, MD (2) · George KK Lau, MD (2) · Mary J Burton, MD (2) · Roger Trinh, MD (2) · Yan Luo, MD (2) · Andrew L Campbell, MD (1) · Bittoo Kanwar (1) · Daniel Cohen (1)
PMID 29377566, PMID 26321288, PMID 20615566, PMID 23281974, PMID 23281975, PMID 23439262, PMID 23439365, PMID 24262278, PMID 24657484, PMID 24720679, PMID 24720703, PMID 24818763, PMID 25386767, PMID 25451053, PMID 25644279, PMID 25839406, PMID 26147154, PMID 26248955, PMID 26596948, PMID 27084721, PMID 27115431, PMID 27415157, PMID 27762283, PMID 27882706, PMID 27917405, PMID 28004322, PMID 28137633, PMID 28282271, PMID 28599618, PMID 28842997, PMID 29377515, PMID 30853642, PMID 32451952, PMID 37671831
2015 (2), 2009 (1), 2014 (1)